Tekst her...Tekst her...
1. Regresjonstestkapittel numero uno
Intern høring:
Internhøring
Ingress...
Sterk anbefaling vil gjelde for de aller fleste pasienter i de aller fleste situasjoner. Uttrykk som brukes er "bør" og "anbefaler". Hvis anbefalingen er så klart faglig forankret at det sjelden er forsvarlig ikke å følge den, brukes uttrykkene "skal" og "må".
Intern høring:
Internhøring
Regresjonstestanbefaling numero uno tekst her. Regresjonstestanbefaling numero uno tekst her. Regresjonstestanbefaling numero uno tekst her. Regresjonstestanbefaling numero uno tekst her.
Praktisk info
Begrunnelse Begrunnelse Begrunnelse
Fordeler og ulemper
Vurdering - Fordeler og ulemper
Kvalitet på dokumentasjonen
Vurdering - Kvalitet på dokumentasjon
Verdier og preferanser
Vurdering - Verdier og preferanser
Ressurshensyn
Vurdering - Ressurshensyn
Populasjon (P)
Pasienter med TIA
Tiltak (I)
Rask utredning og behandling i sykehus
Sammenligning (C)
Annen organisering av behandlingstilbudet
Beskrivelse av inkluderte studier
Abou-Alfa, G. K. L. G. M. K. e. a. (2022). Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evidence, 1(8)
Azoulay, D., Ramos, E., Casellas-Robert, M., Salloum, C., Llado, L., Nadler, R., Busquets, J., Caula-Freixa, C., ... Lim, C. (2021). Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension. JHEP reports : innovation in hepatology, 3(1), 100190.
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G. Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., ... investigators, S. (2015). Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncology, 16(13), 1344-54.
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y. H., Bodoky, G., Pracht, M., Yokosuka, O., ... Investigators, R. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 389(10064), 56-66.
Bujold, A., Massey, C. A., Kim, J. J., Brierley, J., Cho, C., Wong, R. K., Dinniwell, R. E., Kassam, Z., ... Dawson, L. A. (2013). Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. Journal of Clinical Oncology, 31(13), 1631-9.
Bush, D. A., Smith, J. C., Slater, J. D., Volk, M. L., Reeves, M. E., Cheng, J., Grove, R., & de Vera, M. E. (2016). Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma: Results of an Interim Analysis. International Journal of Radiation Oncology, Biology, Physics, 95(1), 477-482.
Chen, C. P. (2019). Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. Journal of clinical and translational hepatology, 7(2), 183-190.
Chong, C. C. N., Lee, K. F., Cheung, S. Y. S., Chu, C. C. M., Fong, A. K. W., Wong, J., Hui, J. W. Y., Fung, A. K. Y., ... Lai, P. B. S. (2020). Prospective double-blinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma (McRFA trial). HPB, 22(8), 1121-1127.
Costa, L. B., Queiroz, M. A., Barbosa, F. G., Nunes, R. F., Zaniboni, E. C., Ruiz, M. M., Jardim, D., Gomes Marin, J. F., ... Buchpiguel, C. A. (2021). Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism. Radiographics, 41(1), 120-143.
de Graaf, W., van Lienden, K. P., Dinant, S., Roelofs, J. J., Busch, O. R., Gouma, D. J., Bennink, R. J., & van Gulik, T. M. (2010). Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection. Journal of Gastrointestinal Surgery, 14(2), 369-78.
Dhondt, E., Lambert, B., Hermie, L., Huyck, L., Vanlangenhove, P., Geerts, A., Verhelst, X., Aerts, M., ... Defreyne, L. (2022). (90)Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. Radiology, 303(3), 699-710.
El-Gendi, A., El-Shafei, M., El-Gendi, S., & Shawky, A. (2018). Laparoscopic Versus Open Hepatic Resection for Solitary Hepatocellular Carcinoma Less Than 5 cm in Cirrhotic Patients: A Randomized Controlled Study. Journal of Laparoendoscopic and Advanced Surgical Techniques. Part A, 28(3), 302-310.
Eskesen, A. N., Bjoro, K., Aandahl, E. M., Line, P. D., & Melum, E. (2014). Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway--a population-based cohort study. Cancer Epidemiology, 38(6), 741-7.
European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology, 69(1), 182-236.
Garancini, M., Nespoli, S., Romano, F., Uggeri, F., Degrate, L., Okolicsanyi, S., & Gianotti, L. (2018). Surgical management of hepatocellular carcinoma within and beyond BCLC indications in a middle volume center. Journal of Visceral Surgery, 155(4), 275-282.
Glantzounis, G. K., Paliouras, A., Stylianidi, M. C., Milionis, H., Tzimas, P., Roukos, D., Pentheroudakis, G., & Felekouras, E. (2018). The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. European Journal of Surgical Oncology, 44(2), 195-208.
Han, G., Berhane, S., Toyoda, H., Bettinger, D., Elshaarawy, O., Chan, A. W. H., Kirstein, M., Mosconi, C., ... Johnson, P. J. (2020). Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology, 72(1), 198-212.
Hendi, M., Lv, J., & Cai, X. J. (2021). Current status of laparoscopic hepatectomy for the treatment of hepatocellular carcinoma: A systematic literature review. Medicine (Baltimore), 100(50), e27826.
Huang, W. Y., Jen, Y. M., Lee, M. S., Chang, L. P., Chen, C. M., Ko, K. H., Lin, K. T., Lin, J. C., ... Chang, Y. W. (2012). Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. International Journal of Radiation Oncology, Biology, Physics, 84(2), 355-61.
Kelley, R. K., Meyer, T., Rimassa, L., Merle, P., Park, J. W., Yau, T., Chan, S. L., Blanc, J. F., ... Abou-Alfa, G. K. (2020). Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 26(18), 4795-4804.
Kim, T. H., Koh, Y. H., Kim, B. H., Kim, M. J., Lee, J. H., Park, B., & Park, J. W. (2021). Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial. Journal of Hepatology, 74(3), 603-612.
Koh, Y. X., Tan, H. L., Lye, W. K., Kam, J. H., Chiow, A. K. H., Tan, S. S., Choo, S. P., Chung, A. Y. F., & Goh, B. K. P. (2018). Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence. World Journal of Hepatology, 10(6), 433-447.
Kudo, M., Ueshima, K., Ikeda, M., Torimura, T., Tanabe, N., Aikata, H., Izumi, N., Yamasaki, T., ... Arai, Y. (2022). Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer, 11(4), 354-367.
Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., Baron, A., Park, J. W., ... Cheng, A. L. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 391(10126), 1163-1173.
Li, Z. L., Yu, J. J., Guo, J. W., Sui, C. J., Dai, B. H., Zhang, W. G., Chen, T. H., Li, C., ... Yang, T. (2019). Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: A multicenter analysis of 1,066 patients. European Journal of Surgical Oncology, 45(5), 800-807.
Llovet, J. M., Real, M. I., Montana, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., ... Barcelona Liver Cancer, G. (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 359(9319), 1734-9.
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., ... Finn, R. S. (2021). Hepatocellular carcinoma. Nature reviews. Disease primers, 7(1), 6.
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., de Oliveira, A. C., Santoro, A., ... Group, S. I. S. (2008). Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine, 359(4), 378-90.
Mazzaferro, V., Sposito, C., Zhou, J., Pinna, A. D., De Carlis, L., Fan, J., Cescon, M., Di Sandro, S., ... Cucchetti, A. (2018). Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology, 154(1), 128-139.
Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., Camerini, T., Roayaie, S., ... Metroticket Investigator Study, G. (2009). Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncology, 10(1), 35-43.
Peng, Z., Fan, W., Zhu, B., Wang, G., Sun, J., Xiao, C., Huang, F., Tang, R., ... Kuang, M. (2022). Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). Journal of Clinical Oncology, , JCO2200392.
Qin, S., Bai, Y., Lim, H. Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T. S., Bhudhisawasdi, V., ... Sun, Y. (2013). Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. Journal of Clinical Oncology, 31(28), 3501-8.
Rajyaguru, D. J., Borgert, A. J., Smith, A. L., Thomes, R. M., Conway, P. D., Halfdanarson, T. R., Truty, M. J., Kurup, A. N., & Go, R. S. (2018). Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database. Journal of Clinical Oncology, 36(6), 600-608.
Reig, M., Forner, A., Rimola, J., Ferrer-Fabrega, J., Burrel, M., Garcia-Criado, A., Kelley, R. K., Galle, P. R., ... Bruix, J. (2022). BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology, 76(3), 681-693.
Ruff, S. M., Rothermel, L. D., Diggs, L. P., Wach, M. M., Ayabe, R. I., Martin, S. P., Boulware, D., Anaya, D., ... Hernandez, J. M. (2020). Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection. HPB, 22(7), 1004-1010.
Salem, R., Johnson, G. E., Kim, E., Riaz, A., Bishay, V., Boucher, E., Fowers, K., Lewandowski, R., & Padia, S. A. (2021). Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology, 74(5), 2342-2352.
Shindoh, J., Truty, M. J., Aloia, T. A., Curley, S. A., Zimmitti, G., Huang, S. Y., Mahvash, A., Gupta, S., ... Vauthey, J. N. (2013). Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. Journal of the American College of Surgeons, 216(2), 201-9.
Tsilimigras, D. I. ,. M. R. ,. P. A. Z. ,. M. D. ,. S. K. ,. B. F. ,. R. F. ,. M. H. P. ,. S. S. ,. S. O. ,. L. V. ,. P. G. A. ,. P. I. ,. G. R. ,. A. S. ,. M. G. ,. W. A. ,. G. A. ,. H. T. ,. P. T. M. (2020). Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria.. Annals of Surgery, 272 (4), 574-581.
Vauthey, J. N., Abdalla, E. K., Doherty, D. A., Gertsch, P., Fenstermacher, M. J., Loyer, E. M., Lerut, J., Materne, R., ... Denys, A. (2002). Body surface area and body weight predict total liver volume in Western adults. Liver Transplantation, 8(3), 233-40.
Vogl, T. J., Lammer, J., Lencioni, R., Malagari, K., Watkinson, A., Pilleul, F., Denys, A., & Lee, C. (2011). Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR: American Journal of Roentgenology, 197(4), W562-70.
Wahl, D. R., Stenmark, M. H., Tao, Y., Pollom, E. L., Caoili, E. M., Lawrence, T. S., Schipper, M. J., & Feng, M. (2016). Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. Journal of Clinical Oncology, 34(5), 452-9.
Wong, T. C., Lee, V. H., Law, A. L., Pang, H. H., Lam, K. O., Lau, V., Cui, T. Y., Fong, A. S., ... Lo, C. M. (2021). Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant. Hepatology, 74(5), 2580-2594.
Yang, D. J., Luo, K. L., Liu, H., Cai, B., Tao, G. Q., Su, X. F., Hou, X. J., Ye, F., ... Tian, Z. Q. (2017). Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma. Oncotarget, 8(2), 2960-2970.
Yao, F. Y., Mehta, N., Flemming, J., Dodge, J., Hameed, B., Fix, O., Hirose, R., Fidelman, N., ... Roberts, J. P. (2015). Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology, 61(6), 1968-77.
Yao, F. Y., Kerlan, R. K. ,. J., Hirose, R., Davern, T. J. ,. 3., Bass, N. M., Feng, S., Peters, M., Terrault, N., ... Roberts, J. P. (2008). Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology, 48(3), 819-27.
Yao, F. Y., Ferrell, L., Bass, N. M., Watson, J. J., Bacchetti, P., Venook, A., Ascher, N. L., & Roberts, J. P. (2001). Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology, 33(6), 1394-403.
Zaydfudim, V. M., Vachharajani, N., Klintmalm, G. B., Jarnagin, W. R., Hemming, A. W., Doyle, M. B., Cavaness, K. M., Chapman, W. C., & Nagorney, D. M. (2016). Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria. Annals of Surgery, 264(4), 650-8.
Zhu, A. X., Kang, Y. K., Yen, C. J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., ... investigators, R. s. (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 20(2), 282-296.
Last update:
01. mai 2024
| See previous versions
Birolle
Last update: 01. mai 2024